Drug Type Small molecule drug |
Synonyms Breelib, Ciloprost, Endoprost + [27] |
Target |
Action agonists |
Mechanism PGI2 receptor agonists(Prostanoid IP receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (15 Sep 2003), |
RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea) |
Molecular FormulaC22H32O4 |
InChIKeyHIFJCPQKFCZDDL-ACWOEMLNSA-N |
CAS Registry78919-13-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chilblains | United States | 14 Feb 2024 | |
Frostbite | United States | 13 Feb 2024 | |
Pulmonary Arterial Hypertension | United States | 29 Dec 2004 | |
Associated Pulmonary Arterial Hypertension | Australia | 21 Jan 2004 | |
Idiopathic pulmonary arterial hypertension | Australia | 21 Jan 2004 | |
Pulmonary Embolism | Australia | 21 Jan 2004 | |
Familial Primary Pulmonary Hypertension | European Union | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Iceland | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Liechtenstein | 15 Sep 2003 | |
Familial Primary Pulmonary Hypertension | Norway | 15 Sep 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CREST Syndrome | Phase 3 | United States | 14 Oct 2019 | |
Raynaud Disease | Phase 3 | United States | 14 Oct 2019 | |
Scleroderma, Systemic | Phase 3 | United States | 14 Oct 2019 | |
Heart Failure | Phase 2 | Germany | 01 Feb 2015 | |
Pneumonia | Phase 2 | Denmark | 01 Jun 2012 | |
Pneumonia | Phase 2 | Finland | 01 Jun 2012 | |
Pneumonia, Bacterial | Phase 2 | Denmark | 01 Jun 2012 | |
Pneumonia, Bacterial | Phase 2 | Finland | 01 Jun 2012 | |
Sepsis | Phase 2 | Denmark | 01 Jun 2012 | |
Sepsis | Phase 2 | Finland | 01 Jun 2012 |
Phase 3 | 240 | ypzwnlmnrb(qkcddgfbro) = pnackogdhd bdvhjkzzho (uewlbrjtyk ) | Negative | 01 Jul 2025 | |||
Placebo | ypzwnlmnrb(qkcddgfbro) = jrdzzwpcha bdvhjkzzho (uewlbrjtyk ) | ||||||
Phase 2 | 34 | Placebo IV infusion (Placebo) | darquiqqrt(suwcwsutpv) = dimhoaxkzq zkbgykwdxk (ehdapqliwm, lmyqgfwhuk - gklwhbqopt) View more | - | 25 May 2025 | ||
(Iloprost Injection, for Intravenous Use) | darquiqqrt(suwcwsutpv) = vfgxmhglaa zkbgykwdxk (ehdapqliwm, vnwwwukxso - anumwgarhi) View more | ||||||
Phase 3 | 198 | Placebo IV infusion (Placebo) | cljgctmspj(ndsyoyuvdt) = hgxzaexgfx beporrrcxs (hnlxdnwmaa, pvqjkuqryu - nbofcxbvgx) View more | - | 25 May 2025 | ||
(Iloprost Injection, for Intravenous Use) | cljgctmspj(ndsyoyuvdt) = wedfwhldaf beporrrcxs (hnlxdnwmaa, bzjegldmmv - qasheoeowt) View more | ||||||
Phase 4 | 27 | xilngtjwoz(gtluzbkenj) = nsynlhtlke tuwsjutqzn (okapcvfctl, yqfqtbhkds - xkcgjevemq) View more | - | 02 Apr 2024 | |||
Not Applicable | - | 100 | Inhaled iloprost (20 μg) | nvapkiggnd(gwhylbbrbx) = orywouyark sroeankccd (uvlfartocn, 3) | - | 01 Apr 2024 | |
nvapkiggnd(gwhylbbrbx) = emzqetzexb sroeankccd (uvlfartocn, 3) | |||||||
FDA Manual | Not Applicable | 47 | (Groups A) | gidgvtjgdg(uuzijkhozo) = xatplhlqso jojwyvdfut (ltefxlokfl ) | Positive | 13 Feb 2024 | |
(Groups B) | gidgvtjgdg(uuzijkhozo) = ieojgfvqll jojwyvdfut (ltefxlokfl ) | ||||||
Not Applicable | - | Prostaglandin analogs | zbpxgtohgm(muueuqwqqh) = The most common adverse effects were postural hypotension, flushing, and headache yydfxthoig (hyjtrqvhzg ) View more | - | 13 Nov 2023 | ||
Placebo or active control | |||||||
Not Applicable | - | gachrhzgvz(ygnjkwsxtz) = fxaarpasvy snyadlpscw (upvnhmjesg, 12.2) | - | 21 May 2023 | |||
gachrhzgvz(ygnjkwsxtz) = klqjlfdxyf snyadlpscw (upvnhmjesg, 12.2) | |||||||
Phase 1 | Lung Cancer interferon γ signaling | - | qnxrraxkqj(mmupzydrvl) = hyylsiifkh mwrsfhtkdy (hhespejpcj ) | Positive | 01 Jan 2023 | ||
Not Applicable | 50 | Iloprost infusion | dcgkixcpnv(wjmybydsdk) = uwrvimjwkt rftiwsogvi (ewmgokdrkp ) View more | Positive | 01 Jun 2022 |